PortalPublikationenOpioidsubstitutionsbehandlung und Cannabiskonsum

Opioidsubstitutionsbehandlung und Cannabiskonsum

Standard

Opioidsubstitutionsbehandlung und Cannabiskonsum. / Schneider, Udo; Schäfer, Ingo; Hillemacher, Thomas; Cimander, Konrad F; Wedekind, Dirk; Weirich, Steffen; Havemann-Reinecke, Ursula.

in: FORTSCHR NEUROL PSYC, Jahrgang 87, Nr. 10, 10.2019, S. 548-553.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schneider, U, Schäfer, I, Hillemacher, T, Cimander, KF, Wedekind, D, Weirich, S & Havemann-Reinecke, U 2019, 'Opioidsubstitutionsbehandlung und Cannabiskonsum', FORTSCHR NEUROL PSYC, Jg. 87, Nr. 10, S. 548-553. https://doi.org/10.1055/a-0918-5961

APA

Schneider, U., Schäfer, I., Hillemacher, T., Cimander, K. F., Wedekind, D., Weirich, S., & Havemann-Reinecke, U. (2019). Opioidsubstitutionsbehandlung und Cannabiskonsum. FORTSCHR NEUROL PSYC, 87(10), 548-553. https://doi.org/10.1055/a-0918-5961

Vancouver

Schneider U, Schäfer I, Hillemacher T, Cimander KF, Wedekind D, Weirich S et al. Opioidsubstitutionsbehandlung und Cannabiskonsum. FORTSCHR NEUROL PSYC. 2019 Okt;87(10):548-553. https://doi.org/10.1055/a-0918-5961

Bibtex

@article{0c5dd1d54d574637ba52dcfd5371a07d,
title = "Opioidsubstitutionsbehandlung und Cannabiskonsum",
abstract = "OBJECTIVES: More than 30 % of patients participating in an opioid maintenance program consume cannabis. This article describes the effects of additional cannabis use during an opioid maintenance treatment program.METHODS: Narrative literature research using online publication databases (MedLine, PubMed) RESULTS: The additional use of cannabis during an opioid maintenance treatment program may have negative side effects.CONCLUSION: Cannabis use should be discussed with the patient. It is in principle not a reason for discontinuing an opioid maintenance treatment program.",
keywords = "Analgesics, Opioid/therapeutic use, Cannabis/adverse effects, Humans, Marijuana Smoking/adverse effects, Opioid-Related Disorders/therapy",
author = "Udo Schneider and Ingo Sch{\"a}fer and Thomas Hillemacher and Cimander, {Konrad F} and Dirk Wedekind and Steffen Weirich and Ursula Havemann-Reinecke",
year = "2019",
month = oct,
doi = "10.1055/a-0918-5961",
language = "Deutsch",
volume = "87",
pages = "548--553",
journal = "FORTSCHR NEUROL PSYC",
issn = "0720-4299",
publisher = "Georg Thieme Verlag KG",
number = "10",

}

RIS

TY - JOUR

T1 - Opioidsubstitutionsbehandlung und Cannabiskonsum

AU - Schneider, Udo

AU - Schäfer, Ingo

AU - Hillemacher, Thomas

AU - Cimander, Konrad F

AU - Wedekind, Dirk

AU - Weirich, Steffen

AU - Havemann-Reinecke, Ursula

PY - 2019/10

Y1 - 2019/10

N2 - OBJECTIVES: More than 30 % of patients participating in an opioid maintenance program consume cannabis. This article describes the effects of additional cannabis use during an opioid maintenance treatment program.METHODS: Narrative literature research using online publication databases (MedLine, PubMed) RESULTS: The additional use of cannabis during an opioid maintenance treatment program may have negative side effects.CONCLUSION: Cannabis use should be discussed with the patient. It is in principle not a reason for discontinuing an opioid maintenance treatment program.

AB - OBJECTIVES: More than 30 % of patients participating in an opioid maintenance program consume cannabis. This article describes the effects of additional cannabis use during an opioid maintenance treatment program.METHODS: Narrative literature research using online publication databases (MedLine, PubMed) RESULTS: The additional use of cannabis during an opioid maintenance treatment program may have negative side effects.CONCLUSION: Cannabis use should be discussed with the patient. It is in principle not a reason for discontinuing an opioid maintenance treatment program.

KW - Analgesics, Opioid/therapeutic use

KW - Cannabis/adverse effects

KW - Humans

KW - Marijuana Smoking/adverse effects

KW - Opioid-Related Disorders/therapy

U2 - 10.1055/a-0918-5961

DO - 10.1055/a-0918-5961

M3 - SCORING: Zeitschriftenaufsatz

C2 - 31404930

VL - 87

SP - 548

EP - 553

JO - FORTSCHR NEUROL PSYC

JF - FORTSCHR NEUROL PSYC

SN - 0720-4299

IS - 10

ER -